NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

This is a pretty ugly scenario both on when we get TLD abs describes a trial failure being whitewashed with a journal article (hence why NEJM or the Lancet would have issues) and so I hope you’re wrong. It certainly puts paid to the idea of DCVax-L being the next SOC. Really hope you’re wrong.